The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study

Background: In a long-term event-driven trial, macitentan has demonstrated beneficial time to clinical worsening in patients with pulmonary arterial hypertension (PAH) and reduced PAH-related hospitalization rates compared with placebo. Macitentan is the most recently approved endothelin receptor an...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yusi Chen, Jun Luo, Jingyuan Chen, Eugene Kotlyar, Zilu Li, Wenjie Chen, Jiang Li
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-01-01
coleção:	Frontiers in Pharmacology
Assuntos:	pulmonary arterial hypertension macitentan ambrisentan endothelin receptor antagonist real-word study
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2021.811700/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!